Related Experiment Video

Updated: Jun 13, 2025

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

14.9K

MEK inhibitors in oncology: a patent review and update (2016 - present)

Anjali Suryavanshi1, Vandana1, Yugal Kishor Shukla1

  • 1Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, India.

Expert Opinion on Therapeutic Patents
|September 14, 2024
PubMed
Abstract

Insights

Mitogen-activated protein kinase (MEK) inhibitors, especially in combination therapies, show significant promise for treating various cancers. These targeted approaches are particularly effective against resistant or relapsed malignancies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Mitogen-activated protein kinase (MEK) is crucial in the Ras/Raf/MEK/ERK pathway, regulating cell growth and development.
  • MEK deregulation is linked to various cancers, making it a key therapeutic target.
  • MEK inhibitors are being explored for cancer treatment, particularly in combination strategies.

Purpose of the Study:

  • To review patent literature on MEK inhibitors in oncology from 2016 to May 2024.
  • To analyze combination products and structural insights of MEK inhibitors.
  • To assess the therapeutic potential of MEK inhibitors in various malignancies.

Main Methods:

  • Comprehensive patent literature search (2016-2024).
  • Databases searched: PubMed, Scopus, Espacenet, Web of Science, WIPO, Google Patents.
  • Analysis of MEK inhibitors, combination therapies, and structural data.

Main Results:

  • MEK inhibitors combined with other kinase inhibitors (e.g., BRaf, KRas, PI3K) demonstrate significant anti-proliferative activity.
  • Combinations with PD-1, EGFR, BTK, and VEGF inhibitors show promise in colorectal, pancreatic, breast cancers, melanoma, and multiple myeloma.
  • Dual or multi-targeted approaches offer improved and precise treatment for resistant cancers.

Conclusions:

  • MEK inhibitors are vital in developing targeted cancer therapies.
  • Combination therapies involving MEK inhibitors show enhanced efficacy in diverse and resistant cancers.
  • Future research should focus on optimizing these multi-targeted strategies for better patient outcomes.
Keywords:
CancerMEKclinical trialsinhibitorsmutationpatentpersonalized medicine

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

252
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis00:06

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K